Biote (NASDAQ: BTMD) Q1 2026 results hit by recall but guidance held
Rhea-AI Filing Summary
Biote Corp. reported first quarter 2026 revenue of $44.9 million, down 8.3% from $49.0 million, as procedure volumes were hurt by a voluntary recall of certain hormone pellet products. Gross margin slipped to 68.9% from 74.3%, and operating income fell to $3.2 million from $9.7 million.
Net income declined to $2.7 million (diluted EPS $0.06) from $15.8 million ($0.37), largely because the gain from changes in earnout liabilities dropped to $2.1 million from $10.7 million. Adjusted EBITDA was $8.7 million, a 36.6% decrease, with margin down to 19.4% from 28.1%.
Dietary supplements revenue grew 19.1% to $11.0 million, partly offsetting a 13.2% decline in procedure revenue to $31.3 million. Management reaffirmed 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million, and continues to expect procedure revenue to return to growth in the second half of 2026.
Positive
- 2026 outlook reaffirmed: Management maintained guidance for 2026 revenue above $190 million and Adjusted EBITDA above $38 million, and still expects procedure revenue to return to growth in the second half of 2026.
- Supplements growth offset weakness: Dietary supplements revenue grew 19.1% year over year to $11.0 million, providing a growing revenue stream alongside the more pressured procedure business.
Negative
- Profitability sharply weaker: Net income dropped to $2.7 million from $15.8 million and Adjusted EBITDA fell 36.6% to $8.7 million, with margin contracting from 28.1% to 19.4%.
- Recall-driven disruption and margin pressure: A voluntary recall of certain hormone pellets reduced procedure revenue by contributing to a 13.2% decline and pushed gross margin down to 68.9% from 74.3%.
- Leverage and cash position: As of March 31, 2026, total liabilities of $137.0 million exceeded total assets of $89.0 million, while cash and cash equivalents fell to $5.3 million from $24.1 million at year-end 2025.
Insights
Q1 revenue and profit declined on recall disruption, but 2026 guidance was reaffirmed.
Biote posted Q1 2026 revenue of $44.9M, down 8.3%, as procedure revenue fell 13.2% to $31.3M after a voluntary recall of certain hormone pellets. Gross margin compressed to 68.9% from 74.3% due to higher third-party sourcing costs and lower manufacturing efficiency.
Net income dropped to $2.7M from $15.8M, mainly because the gain from changes in earnout liabilities shrank to $2.1M from $10.7M. Adjusted EBITDA declined 36.6% to $8.7M, and margin fell to 19.4% from 28.1%, reflecting lower sales and higher operating expenses.
Despite weaker quarterly results and cash declining to $5.3M as of March 31, 2026, management maintained full-year 2026 guidance for revenue above $190M and Adjusted EBITDA above $38M. They also reiterated expectations for procedure revenue to return to growth in the second half of 2026, assuming recall-related headwinds ease.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
Adjusted EBITDA margin financial
earnout liabilities financial
TRA liability financial
voluntary recall financial
non-GAAP financial measures financial
Earnings Snapshot
For 2026, Biote guides to revenue above $190 million and Adjusted EBITDA above $38 million, with procedure revenue expected to return to growth in the second half of 2026 and dietary supplements revenue growing at a mid to high single digit rate from 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On May 6, 2026, biote Corp., a Delaware corporation (the “Company”) issued a press release to report the Company’s financial results for the first quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).
The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release, dated May 6, 2026. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
biote Corp. |
|
|
|
|
Date: |
May 6, 2026 |
By: |
/s/ Bret Christensen |
|
|
|
Bret Christensen |
Biote Reports First Quarter 2026 Financial Results
Sales team expansion on track and nearing targeted level
Return to procedure growth expected in second half of 2026
First Quarter 2026 Financial Highlights
IRVING, TX–(BUSINESS WIRE)–May 6, 2026–Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners’ patients, today announced financial results for the first quarter ended March 31, 2026.
“During the first quarter of 2026, we continued to advance our strategic priorities and remained focused on our key objective of restoring sustainable procedure revenue growth,” said Bret Christensen, Biote’s Chief Executive Officer. “Leading indicators of future performance, including the number of newly trained practitioners and new clinic growth, are moving in the right direction, reinforcing our conviction in our strategic initiatives. We remain committed to investing in our commercial organization, and I am pleased to report we are nearing our stated goal of approximately 120 sales representatives.”
Mr. Christensen continued, “First quarter financial results were impacted by supply constraints related to the voluntary recall of certain hormone pellet products. We are increasing inventory levels to ensure continuity of care throughout our clinic network. We continue to emphasize consistent operational execution, supporting our growing network of practitioners and positioning the company for durable, long-term growth.”
2026 First Quarter Financial Review
(All financial result comparisons made are against the prior-year period unless otherwise noted)
Total revenue was $44.9 million, a decrease of 8.3% from $49.0 million. Procedure revenue declined 13.2% to $31.3 million, and was impacted by the voluntary recall of certain hormone pellets shipped by Asteria Health. Dietary supplements revenue grew 19.1% to $11.0 million.
Gross profit margin was 68.9%, as compared to 74.3%, as a result of impacts from the voluntary recall, which included the sourcing of replacement products from our third-party pellet suppliers at higher costs and reduced manufacturing efficiencies at Asteria Health.
_____________________________
1Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP financial measures. Please see “Discussion of non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measure.
Operating income declined to $3.2 million, from $9.7 million. Operating income decreased due to lower sales and gross profit, as well as higher operating expenses.
Net income was $2.7 million and diluted earnings per share attributable to biote Corp. stockholders was $0.06, as compared to net income of $15.8 million and diluted earnings per share attributable to biote Corp. stockholders of $0.37. Net income included a gain of $2.1 million and $10.7 million for the first quarter of 2026 and 2025, respectively, due to changes in the fair value of the earnout liabilities.
Adjusted EBITDA of $8.7 million decreased 36.6% from $13.8 million, while Adjusted EBITDA margin declined to 19.4% from 28.1%. Both Adjusted EBITDA and Adjusted EBITDA margin decreased from the prior year quarter due to lower sales, reduced gross profit and higher operating expenses.
Summary and 2026 Financial Outlook
Mr. Christensen concluded, “I am pleased with the progress and structural improvements we have achieved as an organization over the trailing twelve months. Although we expect to continue to experience headwinds in the second quarter from our voluntary product recall, I believe our strategic actions and investments are laying the groundwork for improved financial performance as the year progresses. As we expect our commercial investments to begin to translate into productivity gains, we continue to anticipate a return to procedure revenue growth in the second half of the year, consistent with our 2026 guidance provided in March.”
($ in millions) |
2026 Guidance |
Revenue |
Above $190 million |
Adjusted EBITDA2 |
Above $38 million |
_____________________________
2 Please see “Forward-Looking Non-GAAP Financial Measures" below for additional information about forward-looking Adjusted EBITDA.
Conference Call:
Biote management will host a conference call to review these results and provide a business update beginning at 5:00 p.m. ET on Wednesday, May 6, 2026. To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). To access a live webcast of the call, interested parties may use the following link: biote Corp. First Quarter Earnings Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the event concludes.
Discussion of Non-GAAP Financial Measures
To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a non-GAAP financial measure that it calculates as net income before interest, taxes
and depreciation and amortization, further adjusted to exclude stock-based compensation, litigation expenses, legal settlements, inventory fair value write-up, transaction-related expenses, restructuring-related expenses, certain other expenses, merger and acquisition expenses, fair value adjustments to certain equity instruments classified as liabilities and other expenses. Below we have provided a reconciliation of Adjusted EBITDA to net income, the most directly comparable GAAP financial measure.
We present Adjusted EBITDA and Adjusted EBITDA margin because it is a key measure used by our management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA and Adjusted EBITDA margin provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management.
Adjusted EBITDA and Adjusted EBITDA margin have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:
In addition, Adjusted EBITDA and Adjusted EBITDA margin are subject to inherent limitations as it reflects the exercise of judgment by Biote’s management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA and Adjusted EBITDA margin alongside other financial performance measures, including net income and our other GAAP results.
Forward-Looking Non-GAAP Financial Measures
The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP financial measures because it could not do so without unreasonable effort due to the unavailability of certain information needed to calculate reconciling items. For example, the Company has not included a reconciliation of projected Adjusted EBITDA to GAAP net income (loss), which is the most directly comparable GAAP measure, for the periods presented in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K. The Company’s projected Adjusted EBITDA excludes certain items that are inherently uncertain and difficult to predict including, but not limited to, share-based compensation expense, income taxes, due diligence expenses and legal expenses. Due to the variability, complexity and limited visibility of the adjusting items that would be excluded from projected Adjusted EBITDA in future periods, management does not forecast them for internal use and therefore cannot create a quantitative projected Adjusted EBITDA to GAAP net income (loss) reconciliation for the periods presented without unreasonable efforts. A quantitative reconciliation of projected Adjusted EBITDA to GAAP net income (loss) for the periods presented would imply a degree of precision and certainty as to these future items that does not exist and could be confusing to investors. From a qualitative perspective, it is anticipated that the differences between projected Adjusted EBITDA to GAAP net income (loss) for the periods presented will consist of items
similar to those described in the financial tables later in this release, including, for example and without limitation, share-based compensation expense, income taxes, due diligence expenses and legal expenses. The timing and amount of any of these excluded items could significantly impact the Company’s GAAP net income (loss) for a particular period. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.
About Biote
Biote advances the healthspan of our Practitioners’ patients by providing innovative hormone optimization and healthy aging solutions. Through our network of Biote certified providers, we collaborate with leading clinicians to restore vitality and promote vibrant aging.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “may,” “can,” “should,” “will,” “outlook,” “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “hope,” “believe,” “seek,” “target,” “continue,” “could,” “might,” “ongoing,” “potential,” “predict,” “would” and other similar expressions, are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: our investment in our sales and technology capabilities and its anticipated benefits on our business; anticipated benefits and successful execution of our organizational restructuring; the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; our ability and the ability of certain third parties to effectively support the manufacturing of bio-identical hormones for prescribers; our and our customers’ sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our ability to protect our intellectual property; the heavy regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs, U.S. trade policy or similar government actions; geopolitical tensions; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and other risks and uncertainties described in the “Risk Factors” section of Biote’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026, and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.
Financial Tables
Biote Corp.
Condensed Consolidated Balance Sheets (In Thousands) (Unaudited)
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
5,320 |
|
|
$ |
24,123 |
|
Accounts receivable, net |
|
|
7,397 |
|
|
|
6,868 |
|
Inventory, net |
|
|
19,881 |
|
|
|
19,064 |
|
Other current assets |
|
|
3,758 |
|
|
|
4,615 |
|
Total current assets |
|
|
36,356 |
|
|
|
54,670 |
|
Property and equipment, net |
|
|
10,701 |
|
|
|
10,753 |
|
Capitalized software, net |
|
|
5,074 |
|
|
|
4,525 |
|
Goodwill |
|
|
5,833 |
|
|
|
5,833 |
|
Intangible assets, net |
|
|
3,957 |
|
|
|
4,266 |
|
Operating lease right-of-use assets |
|
|
2,558 |
|
|
|
2,701 |
|
Deferred tax assets, net |
|
|
24,481 |
|
|
|
24,793 |
|
Other non-current assets |
|
|
72 |
|
|
|
72 |
|
Total assets |
|
$ |
89,032 |
|
|
$ |
107,613 |
|
|
|
|
|
|
|
|
||
Liabilities and Stockholders’ Deficit |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
8,236 |
|
|
$ |
6,826 |
|
Accrued expenses |
|
|
10,282 |
|
|
|
9,806 |
|
Term loan, current |
|
|
6,250 |
|
|
|
6,250 |
|
Deferred revenue, current |
|
|
2,848 |
|
|
|
3,017 |
|
Operating lease liabilities, current |
|
|
610 |
|
|
|
592 |
|
Share repurchase liabilities |
|
|
— |
|
|
|
18,500 |
|
Total current liabilities |
|
|
28,226 |
|
|
|
44,991 |
|
Term loan, net of current portion |
|
|
94,425 |
|
|
|
95,782 |
|
Revolving loans |
|
|
5,000 |
|
|
|
5,000 |
|
Deferred revenue, net of current portion |
|
|
922 |
|
|
|
1,097 |
|
Operating lease liabilities, net of current portion |
|
|
2,137 |
|
|
|
2,298 |
|
Other non-current liability |
|
|
124 |
|
|
|
344 |
|
TRA liability |
|
|
4,190 |
|
|
|
4,386 |
|
Earnout liabilities |
|
|
1,963 |
|
|
|
4,112 |
|
Total liabilities |
|
|
136,987 |
|
|
|
158,010 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ Deficit |
|
|
|
|
|
|
||
Preferred stock |
|
|
— |
|
|
|
— |
|
Class A common stock |
|
|
3 |
|
|
|
3 |
|
Class V voting stock |
|
|
1 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
— |
|
|
|
— |
|
Accumulated deficit |
|
|
(46,032 |
) |
|
|
(49,549 |
) |
Accumulated other comprehensive loss |
|
|
(27 |
) |
|
|
(29 |
) |
Treasury stock, at cost |
|
|
(10,036 |
) |
|
|
(8,965 |
) |
biote Corp.’s stockholders’ deficit |
|
|
(56,091 |
) |
|
|
(58,539 |
) |
Noncontrolling interest |
|
|
8,136 |
|
|
|
8,142 |
|
Total stockholders’ deficit |
|
|
(47,955 |
) |
|
|
(50,397 |
) |
Total liabilities and stockholders’ deficit |
|
$ |
89,032 |
|
|
$ |
107,613 |
|
Biote Corp.
Condensed Consolidated Statements of Operations and Comprehensive Income (In Thousands, except share and per share amounts) (Unaudited)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Revenue: |
|
|
|
|
|
|
||
Product revenue |
|
$ |
43,895 |
|
|
$ |
47,025 |
|
Service revenue |
|
|
1,040 |
|
|
|
1,967 |
|
Total revenue |
|
|
44,935 |
|
|
|
48,992 |
|
Cost of revenue |
|
|
|
|
|
|
||
Cost of products |
|
|
12,745 |
|
|
|
11,654 |
|
Cost of services |
|
|
1,237 |
|
|
|
956 |
|
Cost of revenue |
|
|
13,982 |
|
|
|
12,610 |
|
Selling, general and administrative |
|
|
27,787 |
|
|
|
26,692 |
|
Income from operations |
|
|
3,166 |
|
|
|
9,690 |
|
Other income (expense), net: |
|
|
|
|
|
|
||
Interest expense, net |
|
|
(1,972 |
) |
|
|
(2,905 |
) |
Gain from change in fair value of earnout liabilities |
|
|
2,149 |
|
|
|
10,688 |
|
Other income (expense), net |
|
|
(5 |
) |
|
|
(18 |
) |
Total other income (expense), net |
|
|
172 |
|
|
|
7,765 |
|
Income before provision for income taxes |
|
|
3,338 |
|
|
|
17,455 |
|
Income tax expense |
|
|
662 |
|
|
|
1,616 |
|
Net income |
|
|
2,676 |
|
|
|
15,839 |
|
Less: Net income attributable to noncontrolling interest |
|
|
399 |
|
|
|
2,121 |
|
Net income attributable to biote Corp. stockholders |
|
$ |
2,277 |
|
|
$ |
13,718 |
|
|
|
|
|
|
|
|
||
Other comprehensive income (loss): |
|
|
|
|
|
|
||
Foreign currency translation adjustments |
|
|
2 |
|
|
|
(4 |
) |
Other comprehensive income (loss) |
|
|
2 |
|
|
|
(4 |
) |
Comprehensive income |
|
$ |
2,678 |
|
|
$ |
15,835 |
|
|
|
|
|
|
|
|
||
Net income per common share |
|
|
|
|
|
|
||
Basic |
|
$ |
0.07 |
|
|
$ |
0.44 |
|
Diluted |
|
$ |
0.06 |
|
|
$ |
0.37 |
|
Weighted average common shares outstanding |
|
|
|
|
|
|
||
Basic |
|
|
30,646,356 |
|
|
|
31,485,777 |
|
Diluted |
|
|
35,995,490 |
|
|
|
36,952,961 |
|
Biote Corp.
Condensed Consolidated Statements of Cash Flows (In Thousands) (Unaudited)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Operating Activities |
|
|
|
|
|
|
||
Net income |
|
$ |
2,676 |
|
|
$ |
15,839 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
980 |
|
|
|
857 |
|
Bad debt (recovery) expense |
|
|
(433 |
) |
|
|
773 |
|
Amortization of debt issuance costs |
|
|
206 |
|
|
|
211 |
|
Provision for (recovery of) obsolete inventory |
|
|
(1,118 |
) |
|
|
442 |
|
Non-cash lease expense |
|
|
143 |
|
|
|
133 |
|
Non-cash interest on share repurchase liability |
|
|
— |
|
|
|
1,065 |
|
Share-based compensation expense |
|
|
1,758 |
|
|
|
2,127 |
|
Gain from change in fair value of earnout liabilities |
|
|
(2,149 |
) |
|
|
(10,688 |
) |
Deferred income taxes |
|
|
(206 |
) |
|
|
508 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
(96 |
) |
|
|
(907 |
) |
Inventory |
|
|
301 |
|
|
|
952 |
|
Other assets |
|
|
857 |
|
|
|
545 |
|
Accounts payable |
|
|
1,410 |
|
|
|
(2,478 |
) |
Deferred revenue |
|
|
(344 |
) |
|
|
(28 |
) |
Accrued expenses |
|
|
256 |
|
|
|
(2,665 |
) |
Payments pursuant to TRA |
|
|
(196 |
) |
|
|
(93 |
) |
Operating lease liabilities |
|
|
(143 |
) |
|
|
(126 |
) |
Net cash provided by operating activities |
|
|
3,902 |
|
|
|
6,467 |
|
Investing Activities |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(362 |
) |
|
|
(1,630 |
) |
Purchases of capitalized software |
|
|
(806 |
) |
|
|
(218 |
) |
Net cash used in investing activities |
|
|
(1,168 |
) |
|
|
(1,848 |
) |
Financing Activities |
|
|
|
|
|
|
||
Repurchases of Class A common stock |
|
|
(1,071 |
) |
|
|
— |
|
Borrowings on revolving loans |
|
|
7,500 |
|
|
|
— |
|
Repayments on revolving loans |
|
|
(7,500 |
) |
|
|
— |
|
Principal repayments on term loan |
|
|
(1,563 |
) |
|
|
(1,563 |
) |
Payments on repurchase liability |
|
|
(18,500 |
) |
|
|
— |
|
Distributions |
|
|
(405 |
) |
|
|
(694 |
) |
Net cash used in financing activities |
|
|
(21,539 |
) |
|
|
(2,257 |
) |
Effect of exchange rate changes on cash and cash equivalents |
|
|
2 |
|
|
|
(4 |
) |
Net increase (decrease) in cash and cash equivalents |
|
|
(18,803 |
) |
|
|
2,358 |
|
Cash and cash equivalents at beginning of period |
|
|
24,123 |
|
|
|
39,342 |
|
Cash and cash equivalents at end of period |
|
$ |
5,320 |
|
|
$ |
41,700 |
|
Supplemental Disclosure of Cash Flow Information |
|
|
|
|
|
|
||
Cash paid for interest |
|
$ |
1,758 |
|
|
$ |
2,016 |
|
Cash paid for income taxes |
|
$ |
120 |
|
|
$ |
2 |
|
Biote Corp.
Reconciliation of Adjusted EBITDA to Net Income (Unaudited)
The following table presents a reconciliation of net income to Adjusted EBITDA, as well as the calculation of net income margin and Adjusted EBITDA margin, for each of the periods indicated.
|
|
Three Months Ended |
|
|||||
|
|
March 31, |
|
|||||
(in thousands) |
|
2026 |
|
|
2025 |
|
||
Net income |
|
$ |
2,676 |
|
|
$ |
15,839 |
|
Interest expense, net(1) |
|
|
1,972 |
|
|
|
2,905 |
|
Income tax expense |
|
|
662 |
|
|
|
1,616 |
|
Depreciation and amortization(2) |
|
|
980 |
|
|
|
857 |
|
Share-based compensation expense(3) |
|
|
1,758 |
|
|
|
2,127 |
|
Litigation expenses-former owner(4) |
|
|
2 |
|
|
|
150 |
|
Litigation-other(5) |
|
|
702 |
|
|
|
465 |
|
Legal settlement and related expenses(6) |
|
|
525 |
|
|
|
36 |
|
Other expenses(7) |
|
|
1,487 |
|
|
|
335 |
|
Merger and acquisition expenses(8) |
|
|
110 |
|
|
|
110 |
|
Gain from change in fair value of earnout liabilities |
|
|
(2,149 |
) |
|
|
(10,688 |
) |
Adjusted EBITDA |
|
$ |
8,725 |
|
|
$ |
13,752 |
|
Total revenue |
|
$ |
44,935 |
|
|
$ |
48,992 |
|
Net income margin(9) |
|
|
6.0 |
% |
|
|
32.3 |
% |
Adjusted EBITDA margin(10) |
|
|
19.4 |
% |
|
|
28.1 |
% |
Investor Relations:
Eric Prouty
AdvisIRy Partners
eric.prouty@advisiry.com
Media:
Press@biote.com